These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 38904200)

  • 1. The pathogenic response of cytotoxic T‑lymphocytes, a common therapeutic target for cancer, has a direct impact on treatment outcomes (Review).
    Luan J; Liu Y; Cao M; Guo X; Guo N
    Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38904200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy.
    Jiang W; He Y; He W; Wu G; Zhou X; Sheng Q; Zhong W; Lu Y; Ding Y; Lu Q; Ye F; Hua H
    Front Immunol; 2020; 11():622509. PubMed ID: 33633741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic CD8
    Iwahori K
    Adv Exp Med Biol; 2020; 1224():53-62. PubMed ID: 32036604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reinvigorating exhausted CD8
    Hossain MA; Liu G; Dai B; Si Y; Yang Q; Wazir J; Birnbaumer L; Yang Y
    Med Res Rev; 2021 Jan; 41(1):156-201. PubMed ID: 32844499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunometabolism of CD8
    Shi H; Chen S; Chi H
    Trends Cancer; 2024 Jul; 10(7):610-626. PubMed ID: 38693002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Emerging Role of CD8
    Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
    Front Immunol; 2018; 9():1904. PubMed ID: 30158938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling.
    Nguyen KB; Spranger S
    J Cell Biol; 2020 Jan; 219(1):. PubMed ID: 31816057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.
    Marcelis L; Antoranz A; Delsupehe AM; Biesemans P; Ferreiro JF; Debackere K; Vandenberghe P; Verhoef G; Gheysens O; Cattoretti G; Bosisio FM; Sagaert X; Dierickx D; Tousseyn T
    Cancer Immunol Immunother; 2020 Sep; 69(9):1751-1766. PubMed ID: 32335702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
    Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating T Cell Immunity in Cancer: Achievements and Prospects.
    Zeng Z; Chew HY; Cruz JG; Leggatt GR; Wells JW
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic adenovirus decreases the proportion of TIM-3
    Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.
    Chiozzini C; Olivetta E; Sanchez M; Arenaccio C; Ferrantelli F; Leone P; Federico M
    J Mol Med (Berl); 2019 Aug; 97(8):1139-1153. PubMed ID: 31161312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
    Mylvaganam G; Yanez AG; Maus M; Walker BD
    Front Immunol; 2019; 10():2109. PubMed ID: 31552045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.